Avasarala, J. “Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab Is Overkill”. Drug Target Insights, vol. 11, no. 1, Nov. 2017, doi:10.33393/dti.2017.1367.